Buscar
Mostrando ítems 21-30 de 55
Artículo
Population pharmacokinetics and pharmacodynamics of fosfomycin in non-critically ill patients with bacteremic urinary infection caused by multidrug-resistant Escherichia coli
(Elsevier, 2018)
Objectives: To describe the population pharmacokinetics of fosfomycin for patients with bacteraemic urinary tract infection (BUTI). The analysis identified optimal regimens on the basis of pharmacodynamic targets and ...
Artículo
Global dissemination of a multidrug resistant Escherichia coli clone
(National Academy of Sciences, 2014-04)
Escherichia coli sequence type 131 (ST131) is a globally disseminated, multidrug resistant (MDR) clone responsible for a high proportion of urinary tract and bloodstream infections. The rapid emergence and successful ...
Artículo
Spanish Multicenter Study of the Epidemiology and Mechanisms of Amoxicillin-Clavulanate Resistance in Escherichia coli
(American Society for Microbiology, 2012-07)
We conducted a prospective multicenter study in Spain to characterize the mechanisms of resistance to amoxicillin-clavu-lanate (AMC) in Escherichia coli. Up to 44 AMC-resistant E. coli isolates (MIC>32/16 g/ml) were collected ...
Artículo
Bacteraemia due to non-ESBL-producing Escherichia coli O25b:H4 sequence type 131: insights into risk factors, clinical features and outcomes
(Elsevier, 2017)
The epidemiology and outcomes of bloodstream infections (BSIs) caused by Escherichia coli ST131 isolates not producing extended-spectrum β-lactamases (ESBLs) are not well defined despite being more prevalent than ESBL-producers. ...
Artículo
Assessing the Impact of SARS-CoV-2 Lineages and Mutations on Patient Survival
(MDPI, 2022)
Objectives: More than two years into the COVID-19 pandemic, SARS-CoV-2 still remains a global public health problem. Successive waves of infection have produced new SARS-CoV-2 variants with new mutations for which the ...
Artículo
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial
(BMJ Publishing Group, 2015)
Introduction Finding therapeutic alternatives to carbapenems in infections caused by extended-spectrum β-lactamase-producing Escherichia coli (ESBL-EC) is imperative. Although fosfomycin was discovered more than 40 years ...
Artículo
Evaluation of temocillin efficacy against KPC-2-producing Klebsiella pneumoniae isolates in a hollow-fibre infection model
(Oxford University Press, 2024-02-09)
Background: Temocillin is an old antimicrobial that is resistant to hydrolysis by ESBLs but has variable activity against carbapenemase-producing Enterobacteriaceae. The current EUCAST susceptibility breakpoints ...
Artículo
Efficacy of Fosfomycin and Its Combination With Aminoglycosides in an Experimental Sepsis Model by Carbapenemase-Producing Klebsiella pneumoniae Clinical Strains
(Frontiers Media, 2021)
Carbapenemase-producing Klebsiella pneumoniae infections are an increasing global threat with scarce and uncertain treatment options. In this context, combination therapies are often used for these infections. The bactericidal ...
Tesis Doctoral
Caracterización de aislados de Escherichia coli de origen clínico y alimentario productores de batalactamasas de espectro extendido
(2014-09-24)
Escherichia coli, perteneciente a la familia Enterobacteriaceae, es el comensal más prevalente en el tracto gastrointestinal de humanos y uno de los principales agentes causantes de un amplio espectro de infecciones en ...
Artículo
Pharmacodynamics of fosfomycin: Insights into clinical use for antimicrobial resistance
(American Society for Microbiology, 2015-09-01)
The aim of this study was to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of fosfomycin against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains that have different ...